Biontech vs United Therapeutics
Biontech and United Therapeutics are similar in size: $3.24bn and $3.18bn of revenue in their latest fiscal years. United Therapeutics grew faster (10.6% against 9.0%). United Therapeutics kept more of each dollar of sales as profit: a net margin of 41.9% against -39.6%.
| Latest fiscal year | BiontechBNTX, 2025 | United TherapeuticsUTHR, 2025 |
|---|---|---|
| Revenue | $3.24bn | $3.18bn |
| Revenue growth | 9.0% | 10.6% |
| Net income | −$1.28bn | $1.33bn |
| Operating margin | -49.0% | 46.9% |
| Net margin | -39.6% | 41.9% |
| Return on equity | -6.0% | 19.7% |
| Free cash flow | $318m | $1.04bn |
| Cash | $9.01bn | $1.56bn |
| Total debt | $0 | — |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | — | $1.00bn |
| Employees | — | 1,400 |
| Market value | $21.84bn | $25.65bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | — | 75 (Strong) |
| Insider trades, 12 months | 0 buys, 27 sales | 1 buys, 2808 sales |